Abstract
Drug developments in the US and EU are becoming increasingly expensive and
time consuming, with new products typically requiring investment of over 4
years and $1billion from concept to commercialization. As a result, China has
emerged as an increasingly attractive option for companies aiming to reduce
such prohibitive investments in time and finance. Human clinical studies have
historically dominated outsourced R&D activities in China, with the country' s
relative lack of capital and expertise being insufficient to facilitate
technologically intensive discovery and pre-clinical work. However, an influx
of western-trained scientists and increasing access to global capital markets
are rapidly extending the development opportunities available to China' s
expanding base of pharma and biotech companies. ' Drug Development
Opportunities in China' is a new report published by Business Insights that
provides a comprehensive review of China' s drug development industry, both in
terms of expanding domestic markets and the country' s role as a third-party
provider of outsourced global drug developments. This report will examine the
methods of expansion adopted by China' s pharma companies, biotech developers
and CRO' s to increase the scale of their drug development operations, in
addition to identifying their therapeutic interests and development lifecycle
focus. It will also provide forecasts for drug development trends in China
over the next five years. Identify the factors attracting global drug
developers to China, assess future growth opportunities within the domestic
pharma and biotech markets and deploy outsourced R&D more effectively with
this new report...
View Cart
